Baron Edmund de Rothschild Commemorative Coin

Obverse: Portrait of Baron de Rothschild. Reverse: Emblem of the State of Israel, inscription

Valour Coin

Obverse: 2 Sheqalim silver coin, number 2 is large over the whole front part of the coin. Reverse: Emblem of the Israeli Army.

Hanukkah lamp from Prague Coin

Obverse: 1 Sheqel silver coin with designs on the sides. Reverse: Hanukkah lamp from Prague, 18th century

Hanukkyia from Prague Coin

Obverse: 2 Sheqalim silver coin, designs on the sides. Reverse: Hanukkah lamp from Prague, 18th century.

Hanukkah lamp from Theresienstadt Coin

Obverse: 1 Sheqel silver coin, number one designed to remind striped clothing of the inmates of concentration camps. Reverse: Hanukkah lamp from Theresienstadt.

Hanukkah lamp from Theresienstadt Coin

Obverse: 2 Sheqalim silver coin, number one designed to remind striped clothing of the inmates of concentration camps. Reverse: Hanukkah lamp from Theresienstadt.

Hanukkah lamp from Yemen Coin

Obverse: 1 Sheqel silver coin, large emblem of the State of Israel. Reverse: Hanukkah lamp from Yemen, inscription written in old Yemenite script.

Hanukka Lamp from Yemen Coin

Obverse: 2 Sheqalim silver coin, large emblem of the State of Israel. Reverse: Hanukkah lamp from Yemen, inscription in the old Yemenite script.

Jerusalem Commemorative Coin

Obverse: Stylized picture of Jerusalem atop mountain surrounded by clouds. Reverse: Bar Kochba coin from Jerusalem. In the center of the coin 4 columns, an arc, symbol of the Torah.

Lod Commemorative Coin

Obverse: Front view of a plane, airport buildings, in the background relief of old buildings in the city. Reverse: City coin of Lod, minted at the beginn9ng of the third century CE by Emperor Caracalla, on the coin a head of Tyche (Fortune) looking to the left, she wears a crown representing city-walls and towers.

Multifaceted roles of curcumin: two sides of a coin!

Introduction: Curcumin has been a front-line topic of mainstream scientific research for a variety of diseases from cancer to Alzheimer's to infectious diseases. Curcumin suppresses the type 1 immune response, which might lead to alleviation of type 1 immune response disorders. However, the inhibition of type 1 immune response might invite infections with opportunistic pathogens. Considering its low bioavailability, several curcumin derivatives have been designed to improve its functionality. Areas covered: This is a consolidated review which aims to compare and contrast diverse aspects of curcumin in variety of diseases. The intricate underlying mechanisms and the functional determinants of curcumin are discussed. Expert opinion: Curcumin being considered as a spicy panacea, is not a remedy for all diseases. However, its ability to act differentially as an antioxidant or pro-oxidant akin to that of a double-edged sword/friend turning foe can be either beneficial or harmful for the host. It exhibits antioxidant properties at concentrations achievable in the body, making the host vulnerable to infections due to the suppression of innate immune responses. With the increase in knowledge of its functional groups, production of analogues of curcumin is underway to enhance its bioavailability and hence its therapeutic potency.

Quantum Random Walks without Coin Toss

We construct a quantum random walk algorithm, based on the Dirac operator instead of the Laplacian. The algorithm explores multiple evolutionary branches by superposition of states, and does not require the coin toss instruction of classical randomised algorithms. We use this algorithm to search for a marked vertex on a hypercubic lattice in arbitrary dimensions. Our numerical and analytical results match the scaling behaviour of earlier algorithms that use a coin toss instruction.

MPI parallel programming of mixed integer optimization problems using CPLEX with COIN-OR

The aim of this technical report is to present some detailed explanations in order to help to understand and use the Message Passing Interface (MPI) parallel programming for solving several mixed integer optimization problems. We have developed a C++ experimental code that uses the IBM ILOG CPLEX optimizer within the COmputational INfrastructure for Operations Research (COIN-OR) and MPI parallel computing for solving the optimization models under UNIX-like systems. The computational experience illustrates how can we solve 44 optimization problems which are asymmetric with respect to the number of integer and continuous variables and the number of constraints. We also report a comparative with the speedup and efficiency of several strategies implemented for some available number of threads.

The addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for advanced colorectal cancer: results of the MRC COIN trial.

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival.
Methods: In this randomised controlled trial, patients who were fit for but had not received previous chemotherapy for advanced colorectal cancer were randomly assigned to oxaliplatin and fluoropyrimidine chemotherapy (arm A), the same combination plus cetuximab (arm B), or intermittent chemotherapy (arm C). The choice of fluoropyrimidine therapy (capecitabine or infused fluouroracil plus leucovorin) was decided before randomisation. Randomisation was done centrally (via telephone) by the MRC Clinical Trials Unit using minimisation. Treatment allocation was not masked. The comparison of arms A and C is described in a companion paper. Here, we present the comparison of arm A and B, for which the primary outcome was overall survival in patients with KRAS wild-type tumours. Analysis was by intention to treat. Further analyses with respect to NRAS, BRAF, and EGFR status were done. The trial is registered, ISRCTN27286448.
Findings: 1630 patients were randomly assigned to treatment groups (815 to standard therapy and 815 to addition of cetuximab). Tumour samples from 1316 (81%) patients were used for somatic molecular analyses; 565 (43%) had KRAS mutations. In patients with KRAS wild-type tumours (arm A, n=367; arm B, n=362), overall survival did not differ between treatment groups (median survival 17·9 months [IQR 10·3—29·2] in the control group vs 17·0 months [9·4—30·1] in the cetuximab group; HR 1·04, 95% CI 0·87—1·23, p=0·67). Similarly, there was no effect on progression-free survival (8·6 months [IQR 5·0—12·5] in the control group vs 8·6 months [5·1—13·8] in the cetuximab group; HR 0·96, 0·82—1·12, p=0·60). Overall response rate increased from 57% (n=209) with chemotherapy alone to 64% (n=232) with addition of cetuximab (p=0·049). Grade 3 and higher skin and gastrointestinal toxic effects were increased with cetuximab (14 vs 114 and 67 vs 97 patients in the control group vs the cetuximab group with KRAS wild-type tumours, respectively). Overall survival differs by somatic mutation status irrespective of treatment received: BRAF mutant, 8·8 months (IQR 4·5—27·4); KRAS mutant, 14·4 months (8·5—24·0); all wild-type, 20·1 months (11·5—31·7).
Interpretation: This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread metastases cannot be recommended.